Commonwealth Biotechnologies, Inc. Announces Move to the OTC Bulletin Board

RICHMOND, Va.–Commonwealth Biotechnologies, Inc. (“CBI”) (CBTE.OB) is pleased to announce that, effective March 25, 2010, the company’s stock began trading on the OTC Bulletin Board under the symbol CBTE.OB. “CBI is very pleased to be trading on the OTC Bulletin Board as it should provide greater exposure for the company and greater liquidity for our shareholders,” said Richard J. Freer, COO of CBI.

“CBI is very pleased to be trading on the OTC Bulletin Board as it should provide greater exposure for the company and greater liquidity for our shareholders”

About CBI

CBI offers cutting-edge research and development products and services to the global life sciences industry. CBI now operates through its wholly owned subsidiary Mimotopes Pty Ltd, Melbourne, Australia, a peptide and discovery chemistry business and Venturepharm (Asia), a contract research consortium specializing in drug discovery and development, process scale-up, formulation development, cGMP manufacturing and clinical trial management.

Forward Looking Statements

No statement made in this press release should be interpreted as an offer to purchase any security. Such an offer can only be made in accordance with the Securities Act of 1933, as amended and applicable state securities laws. Any statements contained in this release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties as identified in CBI’s filings with the Securities and Exchange Commission. Actual results, events or performance may differ materially. Specifically, CBI cannot guaranty that its presence on the OTC Bulletin Board will in any way enhance its exposure or stock liquidity as suggested.

Readers are cautioned not to place undo reliance on these forward-looking statements, which speak only as the date hereof. Further, all forward-looking statements included in this press release are based upon information available to CBI as of the date hereof. CBI assumes no obligation to update any such forward-looking statements.

< | >